A Phase 3 interventional study of Atazanavir powder and Ritonavir oral solution in HIV Infections, sponsored by Bristol-Myers Squibb. Completed at 18 sites in 6 countries. Open to participants aged 3 Months to 66 Months. Per ClinicalTrials.gov, last updated 2018-05-24.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 124 studies testing ritonavir in HIV Infections — 1 open to participants now, 1 under way, 1 of them phase 3. Ritonavir · HIV Infections.
Among the 124 studies testing ritonavir in HIV Infections, this one is the 38th largest by enrollment of the 119 interventional ones that give a count, is one of 6 that started in 2010, is one of 24 in phase 3, and was the 107th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →1 of the 124 studies testing ritonavir in HIV Infections is open now. Recruiting first, the newest first:
University College, London
Ages 4 wk–14 yrs
Ritonavir: first FDA approval 1996 (NORVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 3 Months to 66 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
124 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 38 · Phase 3 25 · Phase 4 24
First in 1998; this study’s year is marked. 6 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 82 is close to the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 46 across the 119 interventional studies. Of the 112 that completed or were terminated, 33 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 124 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
77 studies in HIV Infections by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 73 finished, 9 (12%) have results posted.
Among the 77 studies in HIV Infections by Bristol-Myers Squibb, this one is the 19th largest by enrollment of the 48 interventional ones that give a count, is the only one that started in 2010, is one of 20 in phase 3, and was the 75th registered.
Bristol-Myers Squibb’s HIV Infections studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 124 studies testing ritonavir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 77 in HIV Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether atazanavir powder combined with ritonavir is safe and well tolerated and produces appropriate drug exposure in children ≥3 months to \<6 years of age.
Key Inclusion Criteria:
Confirmed (HIV)-1 infection diagnosed by a positive virologic test result on 2 separate occasions by:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients weighing 5 to \<10 kg received atazanavir (ATV), 150-mg powder dosed in 50-mg packets, and ritonavir (RTV) oral solution, 80 mg. Stage 1: Initial dose was determined by patient's weight on the day of first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage. All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Patients who reached the age of 6 years or a weight of ≥25kg transitioned from the powder to the capsule formulation of ATV. Patients who weighed 15 to \<20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to \<40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
Drug: Atazanavir powder · Drug: Ritonavir oral solution · Drug: Atazanavir capsules · Drug: Ritonavir capsules
Patients weighing 10 to \<15 kg received ATV powder, 200 mg, dosed in 50-mg sachet packets and RTV oral solution, 80 mg. Stage 1: Initial dose was determined by the patient's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Patients who reached the age of 6 years or a weight of ≥25kg transitioned from the powder to the capsule formulation of ATV. Patients who weighed 15 to \<20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to \<40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
Drug: Atazanavir powder · Drug: Ritonavir oral solution · Drug: Atazanavir capsules · Drug: Ritonavir capsules
Patients weighing 15 to \<25 kg received 250 mg of ATV powder dosed in 50-mg sachet packets, with 80 mg of RTV solution. Stage 1: Initial dose was determined by the patient's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Patients who reached the age of 6 years or a weight of ≥25kg transitioned from powder to the capsule formulation of ATV. Patients who weighed 15 to \<20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to \<40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
Drug: Atazanavir powder · Drug: Ritonavir oral solution · Drug: Atazanavir capsules · Drug: Ritonavir capsules
Powder, oral, dosed by weight. Participants who weighed 5 to \<10 kg received atazanavir (ATV), 150 mg, and ritonavir (RTV), 80 mg; those who weighed 10 to \<15 kg received ATV, 200 mg, and RTV, 80 mg; and those who weighed 15 to \<25 kg received ATV, 250 mg, and RTV, 80 mg, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
Also known as: Reyataz, BMS-232632
Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
Also known as: Norvir
Capsules, oral, dosed by weight in Stage 2. Patients who reached the age of 6 years or a weight of ≥25 kg transitioned from the powder to the capsule formulation of atazanavir (ATV). Patients who weighed 15 to \<20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to \<40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
Oral, capsules, 100 mg, administered in Stage 2 with atazanavir capsules, dosed by weight.
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Time frame: From Day 1 to Week 48
Number of Participants With Laboratory Test Results With Worst Toxicity of Grade 3-4
ALT=alanine aminotransferase; SGPT=serum glutamic-pyruvic transaminase; AST=aspartate aminotransferase; SGOT=serum glutamic-oxaloacetic transaminase; ULN=upper limit of normal. Grading by the National Institute of Health Division of AIDs and World Health Organization criteria. Hemoglobin (g/dL): Grade (Gr)1=9.5-11.0; Gr 2=8.0-9.4; Gr 3=6.5-7.9; Gr 4=\<6.5. Neutrophils, absolute (/mm\^3): Gr 1=\>=1000-\<1500; Gr 2= \>=750-\<1000; Gr 3=\>=500-\<750; Gr 4=\<500. ALT/SGPT (\*ULN): Gr 1=1.25-2.5; Gr 2=2.6-5; Gr 3=5.1-10; Gr 4=\>10. AST/SGOT (\*ULN): Gr 1=1.25-2.5; Gr 2=2.6-5; Gr 3=5.1-10; Gr 4=\>10. Alkaline phosphatase(\*ULN): Gr 1=1.25-2.5; Gr 2=2.6-5: Gr 3=5.1-10; Gr 4=\>10. Total bilirubin (\*ULN): Gr 1=1.1-1; Gr 2=1.6-2.5; Gr 3=2.6-5; Gr 4=\>5. Amylase (\*ULN): Gr 1=1.10-39; Gr 2=1.40-2; Gr 3=2.10-5.0; Gr 4=\>5.0. Lipase (\*ULN): Gr 1=1.10-1.39: Gr 2=1.40-2; Gr 3=2.10-5.0; Gr 4=\>5.0. Uric acid (mg/dL): Gr 1=7.5-10.0; Gr 2=10.1-12.0; Gr 3=12.1-15.0; Gr 4=\>15.
Time frame: After Day 1 to Week 48
Electrocardiogram Changes From Baseline in PR Interval, QTC Bazett, and QTC Fridericia at Week 48
Electrocardiogram parameters were measured at baseline for QTC Bazett, QTC Fridericia, and PR interval. The mean change from baseline at week 48 is reported by arm in milliseconds.
Time frame: From Baseline to Week 48
Number of Participants With Centers for Disease Control (CDC) Class C AIDS Events
CDC Class C events are AIDS-defining events that include recurrent bacterial pneumonia (\>=2 episodes in 12 months); candidiasis of the bronchi, trachea, lungs, or esophagus; invasive cervical carcinoma; disseminated or extrapulmonary coccidioidomycosis; extrapulmonary cryptococcosis; chronic intestinal cryptosporidiosis (\>1 month); cytomegalovirus disease; HIV-related encephalopathy; herpes simplex: chronic ulcers, or bronchitis, pneumonitis, or esophagitis; disseminated or extrapulmonary histoplasmosis; chronic intestinal isosporiasis; Kaposi sarcoma; immunoblastic or primary brain Burkitt lymphoma; mycobacterium avium complex, kansasii, or tuberculosis; mycobacterium, other species; Pneumocystis carinii pneumonia; progressive multifocal leukoencephalopathy; Salmonella septicemia; recurrent toxoplasmosis of brain; HIV wasting syndrome (involuntary weight loss \>10% of baseline body weight) with chronic diarrhea or chronic weakness and documented fever for ≥1 month.
Time frame: From Day 1 to Week 48
Percentage of Participants With HIV RNA Levels <50 c/mL and <400 c/mL at Week 48 by Treatment/Weight
The definition of virologic success included HIV RNA levels \<50 c/mL or 400 c/mL at the Week 48 analysis window. .
Time frame: At Week 48
Percentage of Participants With HIV RNA Levels <50 c/mL and <400 c/mL at Week 48 by Prior Antiretroviral (ARV) Treatment Status
The definition of virologic success included HIV RNA levels \<50 c/mL or \<400 c/mL at the Week 48 analysis.
Time frame: From Day 1 to Week 48
Mean Change From Baseline in HIV RNA Levels at Week 48 by Treatment/Weight
Participants who received at least 1 dose of atazanavir (ATV) and had an HIV RNA measurement on ATV powder at did not switch to the capsule formulation before Week 48
Time frame: From Baseline to Week 48
Mean Change From Baseline in HIV RNA Levels at Week 48 by Prior Antiretroviral (ARV) Treatment Status
Time frame: From Baseline to Week 48
CD4 Cell Count Changes From Baseline at Week 48 by Treatment/Weight
Time frame: From Baseline to Week 48
CD4 Cell Count Changes From Baseline at Week 48 by Prior Antiretroviral (ARV) Treatment Status
Time frame: From Baseline to Week 48
Mean CD4 Percent Changes From Baseline at Week 48 by Treatment/Weight
Time frame: From Baseline to Week 48
Mean CD4 Percent Changes From Baseline at Week 48 by Antiretroviral (ARV) Treatment Status
Time frame: From Baseline to Week 48
Number of Participants Who Acquired Phenotypic Resistance to Atazanavir or Atazanovir/Ritonavir
Criteria for resistance testing= meeting at least 1 of the following: \<1 log10 drop from baseline in HIV RNA level by Week 16 and confirmed by a second HIV RNA level; an HIV RNA level \>200 copies/mL after Week 24, confirmed by a second HIV RNA level; repeated HIV RNA levels ≥50 copies/mL after Week 48; an HIV RNA level ≥400 copies/mL confirmed by a second HIV RNA level of ≥400 copies/mL at any time in a participant who had previously achieved a plasma HIV RNA level \<50 copies/mL; or discontinued due to lack of efficacy. Virologic failure was defined as an incomplete virologic response to therapy or as a viral rebound after the achievement of virologic suppression. The phenotypic resistance to a drug is defined as a fold change (ie, ratio of the 50% inhibitory concentration \[IC50\] of the clinical isolate to the IC50 of the reference strain) greater than the cut-off for reduced susceptibility.
Time frame: After Day 1 to Week 48
Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of Atazanavir and Ritonavir
Time frame: At Week 2 at Hour 0 predose and at Hours 1.5, 2.5, 4, 6, 8, 12, and 24 postdose
Area Under the Concentration Curve (in 1 Dosing Interval From Time 0 to 24 Hours Post Observed Dose) (AUC[TAU])of Atazanavir and Ritonavir
Time frame: At Week 2 at Hour 0 predose and at Hours 1.5, 2.5, 4, 6, 8, 12, and 24 postdose
Time to Maximum Observed Concentration (Tmax) of Atazanavir and Ritonavir
Time frame: At Week 2 at Hour 0 predose and at Hours 1.5, 2.5, 4, 6, 8, 12, and 24 postdose
Apparent Total Body Clearance (CLT/F) of Atazanavir and Ritonavir
Calculated as dose divided by AUC(TAU). AUC(TAU)=area under the concentration-time curve in 1 dosing interval from time 0 to 24 hours post observed dose.
Time frame: At Week 2
Apparent Total Body Clearance Per Body Weight (CLT/F) Per Kilogram of Atazanavir and Ritonavir
Calculated as CLT/F divided by body weight
Time frame: At Week 2
| Milestone | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg |
|---|---|---|---|
| Started | 21 | 19 | 16 |
| Completed | 17 | 14 | 15 |
| Not completed | 4 | 5 | 1 |
| Withdrew: Adverse event | 4 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 2 | 0 |
| Withdrew: Poor compliance/noncompliance | 0 | 2 | 0 |
| Milestone | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg |
|---|---|---|---|
| Started | 16 | 14 | 15 |
| Completed | 10 | 9 | 9 |
| Not completed | 6 | 5 | 6 |
| Withdrew: No longer met study criteria | 2 | 2 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 1 | 1 | 1 |
| Withdrew: Poor/non-compliance | 2 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
| Participants | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg |
|---|---|---|---|
| Deaths | 0 | 0 | 0 |
| SAEs | 5 | 2 | 4 |
| AEs leading to discontinuation | 4 | 1 | 0 |
The definition of virologic success included HIV RNA levels \<50 c/mL or 400 c/mL at the Week 48 analysis window. .
| Percentage of participants | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg |
|---|---|---|---|
| HIV RNA levels <50 c/mL | 47.6 | 68.4 | 71.4 |
| HIV RNA levels <400 c/mL | 66.7 | 73.7 | 85.7 |
The definition of virologic success included HIV RNA levels \<50 c/mL or \<400 c/mL at the Week 48 analysis.
| Percentage of participants | ARV-experienced | ARV-naive |
|---|---|---|
| HIV RNA levels <50 c/mL | 56.3 | 68.2 |
| HIV RNA levels <400 c/mL | 65.6 | 86.4 |
Participants who received at least 1 dose of atazanavir (ATV) and had an HIV RNA measurement on ATV powder at did not switch to the capsule formulation before Week 48
| Log10 c/mL | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg |
|---|---|---|---|
| Mean Change From Baseline in HIV RNA Levels at Week 48 by Treatment/Weight | -2.61 ± 0.3111 | -2.93 ± 0.1678 | -2.40 ± 0.2412 |
| Log10 c/mL | ARV-experienced | ARV-naive |
|---|---|---|
| Mean Change From Baseline in HIV RNA Levels at Week 48 by Prior Antiretroviral (ARV) Treatment Status | -2.53 ± 0.2452 | -2.81 ± 0.1296 |
| Cells/mm^3 | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg |
|---|---|---|---|
| CD4 Cell Count Changes From Baseline at Week 48 by Treatment/Weight | 550.1 ± 285.24 | 225.3 ± 198.34 | 373.8 ± 68.83 |
ALT=alanine aminotransferase; SGPT=serum glutamic-pyruvic transaminase; AST=aspartate aminotransferase; SGOT=serum glutamic-oxaloacetic transaminase; ULN=upper limit of normal. Grading by the National Institute of Health Division of AIDs and World Health Organization criteria. Hemoglobin (g/dL): Grade (Gr)1=9.5-11.0; Gr 2=8.0-9.4; Gr 3=6.5-7.9; Gr 4=\<6.5. Neutrophils, absolute (/mm\^3): Gr 1=\>=1000-\<1500; Gr 2= \>=750-\<1000; Gr 3=\>=500-\<750; Gr 4=\<500. ALT/SGPT (\*ULN): Gr 1=1.25-2.5; Gr 2=2.6-5; Gr 3=5.1-10; Gr 4=\>10. AST/SGOT (\*ULN): Gr 1=1.25-2.5; Gr 2=2.6-5; Gr 3=5.1-10; Gr 4=\>10. Alkaline phosphatase(\*ULN): Gr 1=1.25-2.5; Gr 2=2.6-5: Gr 3=5.1-10; Gr 4=\>10. Total bilirubin (\*ULN): Gr 1=1.1-1; Gr 2=1.6-2.5; Gr 3=2.6-5; Gr 4=\>5. Amylase (\*ULN): Gr 1=1.10-39; Gr 2=1.40-2; Gr 3=2.10-5.0; Gr 4=\>5.0. Lipase (\*ULN): Gr 1=1.10-1.39: Gr 2=1.40-2; Gr 3=2.10-5.0; Gr 4=\>5.0. Uric acid (mg/dL): Gr 1=7.5-10.0; Gr 2=10.1-12.0; Gr 3=12.1-15.0; Gr 4=\>15.
| Participants | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg |
|---|---|---|---|
| Hemoglobin (n=20, 17, 15) | 2 | 3 | 0 |
| Neutrophils, absolute (n=20, 17, 15) | 3 | 2 | 0 |
| ALT/SGPT (n=20, 18, 15) | 5 | 0 | 1 |
| AST/SGOT (n=20, 18, 15) | 1 | 0 | 0 |
| Alkaline phosphatase (n=20, 18, 15) | 0 | 1 | 0 |
| Total bilirubin (n=20, 18, 15) | 2 | 0 | 3 |
| Amylase (n=20, 18, 15) | 8 | 5 | 1 |
| Lipase (n=20, 18, 15) | 0 | 1 | 1 |
| Uric acid n=20, 18, 15) | 0 | 0 | 1 |
Electrocardiogram parameters were measured at baseline for QTC Bazett, QTC Fridericia, and PR interval. The mean change from baseline at week 48 is reported by arm in milliseconds.
| Milliseconds | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg |
|---|---|---|---|
| PR Interval | 4.9 ± 21.80 | 12.0 ± 8.04 | 6.2 ± 8.54 |
| QTC Bazett | 1.7 ± 17.73 | -3.2 ± 21.78 | -4.2 ± 13.02 |
| QTC Fridericia | 7.9 ± 18.36 | 13.2 ± 18.92 | 4.8 ± 11.49 |
CDC Class C events are AIDS-defining events that include recurrent bacterial pneumonia (\>=2 episodes in 12 months); candidiasis of the bronchi, trachea, lungs, or esophagus; invasive cervical carcinoma; disseminated or extrapulmonary coccidioidomycosis; extrapulmonary cryptococcosis; chronic intestinal cryptosporidiosis (\>1 month); cytomegalovirus disease; HIV-related encephalopathy; herpes simplex: chronic ulcers, or bronchitis, pneumonitis, or esophagitis; disseminated or extrapulmonary histoplasmosis; chronic intestinal isosporiasis; Kaposi sarcoma; immunoblastic or primary brain Burkitt lymphoma; mycobacterium avium complex, kansasii, or tuberculosis; mycobacterium, other species; Pneumocystis carinii pneumonia; progressive multifocal leukoencephalopathy; Salmonella septicemia; recurrent toxoplasmosis of brain; HIV wasting syndrome (involuntary weight loss \>10% of baseline body weight) with chronic diarrhea or chronic weakness and documented fever for ≥1 month.
| Participants | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg |
|---|---|---|---|
| Number of Participants With Centers for Disease Control (CDC) Class C AIDS Events | 1 | 1 | 0 |
| Cells/mm^3 | ARV-experienced | ARV-naive |
|---|---|---|
| CD4 Cell Count Changes From Baseline at Week 48 by Prior Antiretroviral (ARV) Treatment Status | 437.9 ± 253.123 | 352.1 ± 152.600 |
| Percentage of lymphocytes | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg |
|---|---|---|---|
| Mean CD4 Percent Changes From Baseline at Week 48 by Treatment/Weight | 6.1 ± 1.56 | 7.3 ± 2.26 | 8.8 ± 1.14 |
| Percentage of lymphocytes | ARV-experienced | ARV-naive |
|---|---|---|
| Mean CD4 Percent Changes From Baseline at Week 48 by Antiretroviral (ARV) Treatment Status | 4.3 ± 1.316 | 9.8 ± 1.496 |
Criteria for resistance testing= meeting at least 1 of the following: \<1 log10 drop from baseline in HIV RNA level by Week 16 and confirmed by a second HIV RNA level; an HIV RNA level \>200 copies/mL after Week 24, confirmed by a second HIV RNA level; repeated HIV RNA levels ≥50 copies/mL after Week 48; an HIV RNA level ≥400 copies/mL confirmed by a second HIV RNA level of ≥400 copies/mL at any time in a participant who had previously achieved a plasma HIV RNA level \<50 copies/mL; or discontinued due to lack of efficacy. Virologic failure was defined as an incomplete virologic response to therapy or as a viral rebound after the achievement of virologic suppression. The phenotypic resistance to a drug is defined as a fold change (ie, ratio of the 50% inhibitory concentration \[IC50\] of the clinical isolate to the IC50 of the reference strain) greater than the cut-off for reduced susceptibility.
| Participants | ARV-experienced | ARV-naive |
|---|---|---|
| Atazanavir | 0 | 0 |
| Ritonavir | 0 | 0 |
| ng/mL | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg |
|---|---|---|---|
| Atazanavir Cmax | 4131 (1110 to 9660) | 5197 (390 to 15000) | 6172 (3560 to 10400) |
| Atazanavir Cmin | 336 (11.4 to 1330) | 572 (11.2 to 4870) | 698 (238 to 2410) |
| Ritonavir Cmax (n=19, 18, 15) | 2919 (188 to 9160) | 2634 (163 to 17700) | 1838 (582 to 4960) |
| Ritonavir Cmin (n=18, 16, 15) | 41.8 (12.7 to 311) | 143 (14.2 to 1610) | 51.0 (9.0 to 468) |
| ng*h/mL | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg |
|---|---|---|---|
| AUC(TAU) Atazanavir | 32503 (10441 to 94352) | 50305 (6697 to 189971) | 61485 (31599 to 117171) |
| AUC(TAU) Ritonavir (n=19, 18, 15) | 17439 (1322 to 56864) | 20510 (971 to 229777) | 13640 (3376 to 40806) |
| Hours | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg |
|---|---|---|---|
| Tmax Atazanavir | 1.58 (1.40 to 12.0) | 1.97 (1.00 to 6.00) | 4.0 (1.5 to 6.0) |
| Tmax Ritonavir | 1.8 (1.3 to 11.9) | 2.9 (1.0 to 8.0) | 4.0 (1.5 to 6.0) |
Calculated as dose divided by AUC(TAU). AUC(TAU)=area under the concentration-time curve in 1 dosing interval from time 0 to 24 hours post observed dose.
| L/h | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg |
|---|---|---|---|
| CLT/F Atazanavir | 4.61 (1.6 to 14.4) | 3.98 (1.1 to 29.9) | 4.07 (2.1 to 7.9) |
| CLT/F Ritonavir (n=19, 18, 15 | 4.59 (1.4 to 60.5) | 3.90 (0.3 to 82.4) | 5.87 (2.0 to 23.7) |
Calculated as CLT/F divided by body weight
| L/h per kilogram | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg |
|---|---|---|---|
| CLT/F per kilogram Atazanavir | 0.65 (0.2 to 1.8) | 0.32 (0.1 to 2.6) | 0.24 (0.1 to 0.5) |
| CLT/F per kilogram Ritonavir (n=19, 18, 15) | 0.65 (0.2 to 7.5) | 0.32 (0.04 to 5.9) | 0.35 (0.1 to 1.4) |
Collected over From Day 1 to Week 48. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| B/L Weight 5 to Less Than 10 kg | 0/21 (0%) | 7/21 (33.3%) | 21/21 (100%) |
| B/L Weight 10 to Less Than 15 kg | 0/19 (0%) | 5/19 (26.3%) | 18/19 (94.7%) |
| B/L Weight 15 to Less Than 25 kg | 0/16 (0%) | 5/16 (31.3%) | 15/16 (93.8%) |
| Event | B/L Weight 5 to Less Than 10 kg | B/L Weight 10 to Less Than 15 kg | B/L Weight 15 to Less Than 25 kg |
|---|---|---|---|
| PneumoniaInfections and infestations | 2/21 | 0/19 | 0/16 |
| NeutropeniaBlood and lymphatic system disorders | 1/21 | 0/19 | 1/16 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/21 | 0/19 | 1/16 |
| Herpes zoster disseminatedInfections and infestations | 0/21 | 0/19 | 1/16 |
| MeningitisInfections and infestations | 1/21 | 0/19 | 1/16 |
| Otitis media chronicInfections and infestations | 0/21 | 0/19 | 1/16 |
| Varicella zoster virus infectionInfections and infestations | 0/21 | 0/19 | 1/16 |
| Transaminases increasedInvestigations | 0/21 | 0/19 | 1/16 |
| Febrile convulsionNervous system disorders | 0/21 | 0/19 | 1/16 |
| Suicide attemptPsychiatric disorders | 0/21 | 0/19 | 1/16 |
| Event | B/L Weight 5 to Less Than 10 kg | B/L Weight 10 to Less Than 15 kg | B/L Weight 15 to Less Than 25 kg |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 11/21 | 6/19 | 7/16 |
| Upper respiratory tract infectionInfections and infestations | 11/21 | 6/19 | 5/16 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/21 | 6/19 | 7/16 |
| VomitingGastrointestinal disorders | 9/21 | 8/19 | 4/16 |
| GastroenteritisInfections and infestations | 9/21 | 5/19 | 2/16 |
| Oral candidiasisInfections and infestations | 9/21 | 0/19 | 0/16 |
| Viral upper respiratory tract infectionInfections and infestations | 4/21 | 8/19 | 4/16 |
| Otitis mediaInfections and infestations | 8/21 | 4/19 | 4/16 |
| PyrexiaGeneral disorders | 3/21 | 7/19 | 5/16 |
| TonsillitisInfections and infestations | 7/21 | 2/19 | 1/16 |
| Age, Continuous(Months) | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg | Total |
|---|---|---|---|---|
| Mean | 7.3 ± 4.05 | 35.4 ± 11.63 | 52.1 ± 10.49 | 29.6 ± 20.72 |
| Sex: Female, Male(Participants) | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg | Total |
|---|---|---|---|---|
| Female | 10 | 12 | 6 | 28 |
| Male | 11 | 7 | 10 | 28 |
| Race/Ethnicity, Customized(Participants) | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg | Total |
|---|---|---|---|---|
| Not Hispanic or Latino | 0 | 0 | 1 | 1 |
| Not reported | 21 | 19 | 15 | 55 |
| Race/Ethnicity, Customized(Participants) | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg | Total |
|---|---|---|---|---|
| White | 2 | 3 | 6 | 11 |
| Black/African American | 13 | 12 | 7 | 32 |
| Asian | 0 | 1 | 0 | 1 |
| Other | 6 | 3 | 3 | 12 |
| Country(Participants) | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg | Total |
|---|---|---|---|---|
| Chile | 1 | 2 | 3 | 6 |
| Mexico | 2 | 3 | 4 | 9 |
| Peru | 1 | 0 | 1 | 2 |
| South Africa | 17 | 13 | 8 | 38 |
| Thailand | 0 | 1 | 0 | 1 |
| HIV RNA(Log10 c/mL) | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg | Total |
|---|---|---|---|---|
| Mean | 4.77 ± 0.602 | 4.83 ± 0.268 | 4.18 ± 0.727 | 4.62 ± 0.617 |
| HIV RNA(c/mL) | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg | Total |
|---|---|---|---|---|
| <30,000 c/mL | 3 | 2 | 9 | 14 |
| 30,000 to 100,000 c/mL | 0 | 7 | 3 | 10 |
| >100,000 c/mL | 18 | 10 | 4 | 32 |
| CD4 Count(Cells/mm^3) | Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg | Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg | Total |
|---|---|---|---|---|
| Mean | 1594.1 ± 897.19 | 1107.4 ± 643.25 | 661.1 ± 302.60 | 1192.6 ± 784.08 |
3 further baseline measures are reported on the registry.
Ran from Oct 2010 to primary completion in Oct 2012, 23 months.
Results were first posted in Feb 2014, 1 year 4 months after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 23 months is close to that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ritonavir · Atazanavir